Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: Correlation with the angiogenesis and clinical outcome

被引:59
作者
Shao, Zhe [1 ,2 ]
Zhang, Wen-Feng [1 ]
Chen, Xin-Ming [3 ]
Shang, Zheng-Jun [1 ,2 ]
机构
[1] Wuhan Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Wuhan 430079, Peoples R China
[2] Wuhan Univ, Minist Educ, Key Lab Oral Biomed Engn, Wuhan 430079, Peoples R China
[3] Wuhan Univ, Sch & Hosp Stomatol, Dept Oral Pathol, Wuhan 430079, Peoples R China
基金
中国国家自然科学基金;
关键词
EphA2; VEGF; Tongue neoplasms; Neovascularization; Squamous cell carcinoma; Immunohistochemistry;
D O I
10.1016/j.oraloncology.2008.01.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Eph-ephrin binding has been linked to tumor biology and VEGF has been reported to participate in the tumor angiogenesis regulated by Eph-ephrin. The present study was designed to evaluate the expression of EphA2 and VEGF in relation to angiogenesis and clinical outcome in squamous cell carcinoma of oral tongue. Immunohistochemical. staining was used to determine the protein expression levels of EphA2 and VEGF in 59 surgically resected tongue carcinomas and 10 tumor-free mucosas. In all, cases, microvessel density (MVD) was evaluated by counting CD34-reactive endothelial. cells or endothelial. cell clusters. Both EphA2 and VEGF staining activities in squamous cell carcinoma of oral tongue were more significant than those in normal mucosa (P < 0.01). MVD had significant correlations with EphA2 and VEGF expression (P < 0.01). The EphA2, VEGF, and MVD were significantly correlated with tumor size, clinical stage, lymph invasion, recurrence, and distant metastasis (P < 0.05). Multivariate analysis showed EphA2, VEGF expression, MVD, and clinical stage had an independent prognostic effect on overall. survival. We conclude that the overexpression of EphA2 and VEGF are related to malignancy in squamous cell carcinoma of oral tongue. Clinical outcomes raised the possibility that the overexpression of those proteins might contribute to tumor angiogenesis and have prognostic value in tongue cancer. (C) 2008 Elsevier Ltd. ALL rights reserved.
引用
收藏
页码:1110 / 1117
页数:8
相关论文
共 31 条
[1]   Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo [J].
Brantley, DM ;
Cheng, N ;
Thompson, EJ ;
Lin, Q ;
Brekken, RA ;
Thorpe, PE ;
Muraoka, RS ;
Cerretti, DP ;
Pozzi, A ;
Jackson, D ;
Lin, C ;
Chen, J .
ONCOGENE, 2002, 21 (46) :7011-7026
[2]   Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression [J].
Brantley-Sieders, DM ;
Fang, WB ;
Hicks, DJ ;
Zhuang, GL ;
Yu, S ;
Chen, J .
FASEB JOURNAL, 2005, 19 (11) :1884-+
[3]   EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation [J].
Brantley-Sieders, DM ;
Caughron, J ;
Hicks, D ;
Pozzi, A ;
Ruiz, JC ;
Chen, J .
JOURNAL OF CELL SCIENCE, 2004, 117 (10) :2037-2049
[4]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[5]   Inhibition of retinal neovascularization by soluble EphA2 receptor [J].
Chen, J ;
Hicks, D ;
Brantley-Sieders, D ;
Cheng, N ;
McCollum, GW ;
Qi-Werdich, X ;
Penn, J .
EXPERIMENTAL EYE RESEARCH, 2006, 82 (04) :664-673
[6]  
Cheng N, 2002, MOL CANCER RES, V1, P2
[7]   Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors [J].
Cheng, N ;
Brantley, D ;
Bin Fang, W ;
Liu, H ;
Fanslow, W ;
Cerretti, DP ;
Bussell, KN ;
Reith, AD ;
Jackson, D ;
Chen, J .
NEOPLASIA, 2003, 5 (05) :445-456
[8]  
Dankort D L, 1996, Cancer Treat Res, V83, P71
[9]   Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer [J].
Dazzi, C ;
Cariello, A ;
Maioli, P ;
Solaini, L ;
Scarpi, E ;
Rosti, G ;
Lanzanova, G ;
Marangolo, M .
LUNG CANCER, 1999, 24 (02) :81-88
[10]   Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist [J].
Dobrzanski, P ;
Hunter, K ;
Jones-Bolin, S ;
Chang, H ;
Robinson, C ;
Pritchard, S ;
Zhao, H ;
Ruggeri, B .
CANCER RESEARCH, 2004, 64 (03) :910-919